BEAM Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
307.0K
-37.3%
490.0K
-98.5%
31.7M
-72.2%
114.1M
+1076.6%
9.7M
Cost of Revenue
0
0
0
0
0
Gross Profit
307.0K
-37.3%
490.0K
-98.5%
31.7M
-72.2%
114.1M
+1076.6%
9.7M
Operating Expenses
141.6M
+11.3%
127.2M
-8.4%
139.0M
+5.6%
131.6M
-3.6%
136.5M
R&D
110.1M
+15.8%
95.1M
-9.0%
104.5M
+5.3%
99.3M
-9.6%
109.8M
SG&A
31.5M
-1.3%
31.9M
-7.2%
34.4M
+6.7%
32.3M
+20.7%
26.7M
Operating Income
-141322000
-11.5%
-126758000
-18.2%
-107215000
-514.6%
-17445000
+86.2%
-126811000
EBITDA
-135877000
-12.0%
-121348000
-19.4%
-101610000
-762.8%
-11777000
+90.3%
-121251000
Net Income
-134405000
-9.6%
-122678000
-30.1%
-94318000
-138.6%
244.3M
+317.0%
-112571000
EPS (Basic)
$-1.28
-8.5%
$-1.18
-29.7%
$-0.91
-138.4%
$2.37
+315.5%
$-1.10
EPS (Diluted)
$-1.28
-8.5%
$-1.18
-29.7%
$-0.91
-138.4%
$2.37
+315.5%
$-1.10
Shares (Diluted)
104.7M
+0.4%
104.3M
+1.0%
103.3M
+0.2%
103.1M
+0.5%
102.6M
Beam Therapeutics (BEAM) — Financials